Literature DB >> 30733339

Phospholipid regulation of innate immunity and respiratory viral infection.

Dennis R Voelker1, Mari Numata2.   

Abstract

Toll-like receptors (TLRs) coupled to intracellular signaling cascades function as central elements of innate immunity that control transcription of numerous pro-inflammatory genes. Two minor anionic phospholipids present in the pulmonary surfactant complex, palmitoyl-oleoyl-phosphatidylglycerol (POPG) and phosphatidylinositol (PI), antagonize the cognate ligand activation of TLRs 2 and 4. The lipids block recognition of activating ligands by the TLRs, either directly or via the TLR4 coreceptors CD14 and MD2. Antagonism of TLR activation results in inhibition of the initiating step of the pro-inflammatory signaling pathways. Evidence for this mechanism of action comes from direct binding studies between CD14 and MD2 with POPG and PI. Additional evidence for this mechanism of antagonism also comes from monitoring the reduction of protein phosphorylation events that characterize the intracellular signaling by activated TLRs. The pathogenesis of respiratory syncytial virus (RSV) and influenza A virus (IAV) have been linked to TLR4 activation, and we examined the action of POPG and PI as potential antagonists of the pathology of these viruses. Surprisingly, POPG and PI dramatically curtail infection, in addition to inhibiting inflammatory sequelae associated with RSV and IAV infections. The mechanism of action by the lipids is disruption of virus particle binding to host cell plasma membrane receptors, required for viral uptake. The antagonism of activation of TLRs and virus binding to the alveolar epithelium by resident constituents of the pulmonary surfactant system suggests that POPG and PI function in homeostasis, to prevent inflammatory processes that result in reductions in gas exchange within the alveolar compartment.
© 2019 Voelker and Numata.

Entities:  

Keywords:  Toll-like receptors; antiviral agent; antivirals; immunology; inflammation; innate immunity; phospholipids; pulmonary surfactant; respiratory system; signaling; toll receptor; viral entry; virology

Mesh:

Substances:

Year:  2019        PMID: 30733339      PMCID: PMC6433062          DOI: 10.1074/jbc.AW118.003229

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Surfactant proteins A and D bind CD14 by different mechanisms.

Authors:  H Sano; H Chiba; D Iwaki; H Sohma; D R Voelker; Y Kuroki
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

2.  Pulmonary surfactant phosphatidylglycerol inhibits Mycoplasma pneumoniae-stimulated eicosanoid production from human and mouse macrophages.

Authors:  Pitchaimani Kandasamy; Simona Zarini; Edward D Chan; Christina C Leslie; Robert C Murphy; Dennis R Voelker
Journal:  J Biol Chem       Date:  2011-01-04       Impact factor: 5.157

3.  Pulmonary surfactant protein A modulates the cellular response to smooth and rough lipopolysaccharides by interaction with CD14.

Authors:  H Sano; H Sohma; T Muta; S Nomura; D R Voelker; Y Kuroki
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

4.  Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus.

Authors:  E A Kurt-Jones; L Popova; L Kwinn; L M Haynes; L P Jones; R A Tripp; E E Walsh; M W Freeman; D T Golenbock; L J Anderson; R W Finberg
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

Review 5.  Role of pulmonary surfactant components in surface film formation and dynamics.

Authors:  E J Veldhuizen; H P Haagsman
Journal:  Biochim Biophys Acta       Date:  2000-08-25

6.  Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Authors:  L M Haynes; D D Moore; E A Kurt-Jones; R W Finberg; L J Anderson; R A Tripp
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.

Authors:  Mari Numata; Hong Wei Chu; Azzeddine Dakhama; Dennis R Voelker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

Review 8.  Diverse functions of pulmonary collectins in host defense of the lung.

Authors:  Shigeru Ariki; Chiaki Nishitani; Yoshio Kuroki
Journal:  J Biomed Biotechnol       Date:  2012-05-20

9.  Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung.

Authors:  Mari Numata; Yelena V Grinkova; James R Mitchell; Hong Wei Chu; Stephen G Sligar; Dennis R Voelker
Journal:  Int J Nanomedicine       Date:  2013-04-15

Review 10.  PAMPs and DAMPs: signal 0s that spur autophagy and immunity.

Authors:  Daolin Tang; Rui Kang; Carolyn B Coyne; Herbert J Zeh; Michael T Lotze
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

View more
  24 in total

Review 1.  Alveolar type II cells and pulmonary surfactant in COVID-19 era.

Authors:  A Calkovska; M Kolomaznik; V Calkovsky
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

2.  Metabolomics Analysis of PK-15 Cells with Pseudorabies Virus Infection Based on UHPLC-QE-MS.

Authors:  Panrao Liu; Danhe Hu; Lili Yuan; Zhengmin Lian; Xiaohui Yao; Zhenbang Zhu; Xiangdong Li
Journal:  Viruses       Date:  2022-05-27       Impact factor: 5.818

Review 3.  Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.

Authors:  Dan Li; Xianzheng Wang; Yingzhao Liao; Shouchuan Wang; Jinjun Shan; Jianjian Ji
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 4.  Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19).

Authors:  Victor B Hsue; Kyohei Itamura; Arthur W Wu; Elisa A Illing; Kevin J Sokoloski; Bree A Weaver; Benjamin P Anthony; Nathan Hughes; Jonathan Y Ting; Thomas S Higgins
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Huanglong Antitussive Granule Relieves Acute Asthma Through Regulating Pulmonary Lipid Homeostasis.

Authors:  Hua Yan; Guiying Qian; Rui Yang; Zichen Luo; Xianzheng Wang; Tong Xie; Xia Zhao; Jinjun Shan
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

Review 6.  Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids.

Authors:  Mari Numata; Dennis R Voelker
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2022-02-28       Impact factor: 5.228

7.  Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2.

Authors:  Ma'ayan Israeli; Yaara Finkel; Yfat Yahalom-Ronen; Nir Paran; Theodor Chitlaru; Ofir Israeli; Inbar Cohen-Gihon; Moshe Aftalion; Reut Falach; Shahar Rotem; Uri Elia; Ital Nemet; Limor Kliker; Michal Mandelboim; Adi Beth-Din; Tomer Israely; Ofer Cohen; Noam Stern-Ginossar; Adi Bercovich-Kinori
Journal:  Nat Commun       Date:  2022-04-25       Impact factor: 17.694

Review 8.  Alveolar lipids in pulmonary disease. A review.

Authors:  Christina W Agudelo; Ghassan Samaha; Itsaso Garcia-Arcos
Journal:  Lipids Health Dis       Date:  2020-06-03       Impact factor: 3.876

Review 9.  Lipid-Protein and Protein-Protein Interactions in the Pulmonary Surfactant System and Their Role in Lung Homeostasis.

Authors:  Olga Cañadas; Bárbara Olmeda; Alejandro Alonso; Jesús Pérez-Gil
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

Review 10.  Protocols for Enzymatic Fluorometric Assays to Quantify Phospholipid Classes.

Authors:  Shin-Ya Morita; Tokuji Tsuji; Tomohiro Terada
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.